Immunologic Research

, Volume 43, Issue 1–3, pp 128–137 | Cite as

Eosinophils and their interactions with respiratory virus pathogens

  • Helene F. Rosenberg
  • Kimberly D. Dyer
  • Joseph B. Domachowske
Article

Abstract

Eosinophils are implicated in the pathophysiology of respiratory virus infection, most typically in negative roles, such as promoting wheezing and bronchoconstriction in conjunction with virus-induced exacerbations of reactive airways disease and in association with aberrant hypersensitivity responses to viral vaccines. However, experiments carried out in vitro and in vivo suggest positive roles for eosinophils, as they have been shown to reduce virus infectivity in tissue culture and promote clearance of the human pathogen, respiratory syncytial virus in a mouse challenge model. The related natural rodent pathogen, pneumonia virus of mice (PVM), is highly virulent in mice, and is not readily cleared by eosinophils in vivo. Interestingly, PVM replicates in eosinophils and promotes cytokine release. The molecular basis of virus infection in eosinophils and its relationship to disease outcome is currently under study.

Keywords

Eosinophils Inflammation Virus Ribonuclease Cytokine 

References

  1. 1.
    Rothenberg ME, Hogan SP. The eosinophil. Annu Rev Immunol. 2006;24:147–74.PubMedCrossRefGoogle Scholar
  2. 2.
    Jacobsen EA, Taranova AG, Lee NA, Lee JJ. Eosinophils: singularly destructive effector cells or purveyors of immunoregulation? J Allergy Clin Immunol. 2007;119:1313–20.PubMedCrossRefGoogle Scholar
  3. 3.
    Klion AD, Nutman TB. The role of eosinophils in host defense against helminth parasites. J Allergy Clin Immunol. 2004;113:30–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Menzies-Gow A, Robinson DS. Eosinophils, eosinophilic cytokines (interleukin-5), and antieosinophilic therapy in asthma. Curr Opin Pulm Med. 2002;8:33–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Leckie MJ. Anti-interleukin-5 monoclonal antibodies: preclinical and clinical evidence in asthma models. Am J Respir Med. 2003;2:245–59.PubMedGoogle Scholar
  6. 6.
    Humbles AA, Lloyd CM, McMillan SJ, Friend DS, Xanthou G, McKenna EE, et al. A critical role for eosinophils in allergic airways remodeling. Science. 2004;305:1776–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Lee JJ, Lee NA. Eosinophil degranulation: an evolutionary vestige or a universally destructive effector function? Clin Exp Allergy. 2005;35:986–94.PubMedCrossRefGoogle Scholar
  8. 8.
    Jacoby DB. Pathophysiology of airway viral infections. Pulm Pharmacol Ther. 2004;17:333–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Holgate ST. Pathogenesis of asthma. Clin Exp Allergy. 2008;38:872–97.PubMedCrossRefGoogle Scholar
  10. 10.
    Rosenberg HF, Domachowske JB. Eosinophils, eosinophil ribonucleases, and their role in host defense against respiratory virus pathogens. J Leukoc Biol. 2001;70:691–8.PubMedGoogle Scholar
  11. 11.
    Welliver RC. Immunology of respiratory syncytial virus infection: eosinophils, cytokines, chemokines and asthma. Pediatr Infect Dis J. 2000;19:780–3.PubMedGoogle Scholar
  12. 12.
    Smith JA. Neutrophils, host defense, and inflammation: a double-edged sword. J Leukoc Biol. 1994;56:672–86.PubMedGoogle Scholar
  13. 13.
    Serhan CN, Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol. 2005;6:1191–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Pérez-Yarza EG, Moreno A, Lázaro P, Mejías A, Ramilo O. The association between respiratory syncytial virus infection and the development of childhood asthma: a systematic review of the literature. Pediatr Infect Dis J. 2007;26:733–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Mohapatra SS, Boyapalle S. Epidemiologic, experimental, and clinical links between respiratory syncytial virus infection and asthma. Clin Microbiol Rev. 2008;21:495–504.PubMedCrossRefGoogle Scholar
  16. 16.
    Tateno H, Crocker PR, Paulson JC. Mouse Siglec-F and human Siglec-8 are functionally convergent paralogs that are selectively expressed on eosinophils and recognize 6′-sulfo-sialyl Lewis X as a preferred glycan ligand. Glycobiology. 2005;15:1125–35.PubMedCrossRefGoogle Scholar
  17. 17.
    Borchers MT, Ansay T, DeSalle R, Daugherty BL, Shen H, Metzger M, et al. In vitro assessment of chemokine receptor-ligand interactions mediating mouse eosinophil migration. J Leukoc Biol. 2002;71:1033–41.PubMedGoogle Scholar
  18. 18.
    Rosenberg HF, Dyer KD, Tiffany HL, Gonzalez M. Rapid evolution of a unique family of primate ribonuclease genes. Nat Genet. 1995;10:219–23.PubMedCrossRefGoogle Scholar
  19. 19.
    Rosenberg HF, Dyer KD. Eosinophil cationic protein and eosinophil-derived neurotoxin. Evolution of novel function in a primate ribonuclease gene family. J Biol Chem. 1995;270:21539–44.PubMedCrossRefGoogle Scholar
  20. 20.
    Larson KA, Olson EV, Madden BJ, Gleich GJ, Lee NA, Lee JJ. Two highly homologous ribonuclease genes expressed in mouse eosinophils identify a larger subgroup of the mammalian ribonuclease superfamily. Proc Natl Acad Sci USA. 1996;93:12370–5.PubMedCrossRefGoogle Scholar
  21. 21.
    Zhang J, Dyer KD, Rosenberg HF. Evolution of the rodent eosinophil-associated RNase gene family by rapid gene sorting and positive selection. Proc Natl Acad Sci USA. 2000;97:4701–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Domachowske JB, Dyer KD, Bonville CA, Rosenberg HF. Recombinant human eosinophil-derived neurotoxin/RNase 2 functions as an effective antiviral agent against respiratory syncytial virus. J Infect Dis. 1998;177:1458–64.PubMedCrossRefGoogle Scholar
  23. 23.
    Adamko DJ, Yost BL, Gleich GJ, Fryer AD, Jacoby DB. Ovalbumin sensitization changes the inflammatory response to subsequent parainfluenza infection. Eosinophils mediate airway hyperresponsiveness, m(2) muscarinic receptor dysfunction, and antiviral effects. J Exp Med. 1999;190(10):1465–78.PubMedCrossRefGoogle Scholar
  24. 24.
    Phipps S, Lam CE, Mahalingam S, Newhouse M, Ramirez R, Rosenberg HF, et al. Eosinophils contribute to innate antiviral immunity and promote clearance of respiratory syncytial virus. Blood. 2007;110:1578–86.PubMedCrossRefGoogle Scholar
  25. 25.
    Rosenberg HF, Domachowske JB. Pneumonia virus of mice: severe respiratory infection in a natural host. Immunol Lett. 2008;118:6–12.PubMedCrossRefGoogle Scholar
  26. 26.
    Easton AJ, Domachowske JB, Rosenberg HF. Pneumonia virus of mice. In: Cane P, editor. Perspectives in medical virology, vol. 12. The Netherlands: Elsevier; 2006. p. 299–319.Google Scholar
  27. 27.
    Rosenberg HF, Bonville CA, Easton AJ, Domachowske JB. The pneumonia virus of mice infection model for severe respiratory syncytial virus infection: identifying novel targets for therapeutic intervention. Pharmacol Ther. 2005;105:1–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Bonville CA, Rosenberg HF, Domachowske JB. Ribavirin and cysteinyl leukotriene-1 receptor blockade as treatment for severe bronchiolitis. Antiviral Res. 2006;69:53–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Bonville CA, Lau VK, DeLeon JM, Gao JL, Easton AJ, Rosenberg HF, et al. Functional antagonism of chemokine receptor CCR1 reduces mortality in acute pneumovirus infection in vivo. J Virol. 2004;78:7984–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Bonville CA, Easton AJ, Rosenberg HF, Domachowske JB. Altered pathogenesis of severe pneumovirus infection in response to combined antiviral and specific immunomodulatory agents. J Virol. 2003;77:1237–44.PubMedCrossRefGoogle Scholar
  31. 31.
    Bonville CA, Bennett NJ, Koehnlein M, Haines DM, Ellis JA, DelVecchio AM, et al. Respiratory dysfunction and proinflammatory chemokines in the pneumonia virus of mice (PVM) model of viral bronchiolitis. Virology. 2006;349:87–95.PubMedCrossRefGoogle Scholar
  32. 32.
    Castilow EM, Olson MR, Varga SM. Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease. Immunol Res. 2007;39:225–39.PubMedCrossRefGoogle Scholar
  33. 33.
    Dyer KD, Moser JM, Czapiga M, Siegel SJ, Percopo CM, Rosenberg HF. Functionally competent eosinophils differentiated ex vivo in high purity from normal mouse bone marrow. J Immunol. 2008;181:4004–9.PubMedGoogle Scholar
  34. 34.
    Rosenberg HF, Phipps S, Foster PS. Eosinophil trafficking in allergy and asthma. J Allergy Clin Immunol. 2007;119:1303–10.PubMedCrossRefGoogle Scholar
  35. 35.
    Ellis JA, Martin BV, Waldner C, Dyer KD, Domachowske JB, Rosenberg HF. Mucosal inoculation with an attenuated mouse pneumovirus strain protects against virulent challenge in wild type and interferon-gamma receptor deficient mice. Vaccine. 2007;25:1085–95.PubMedCrossRefGoogle Scholar
  36. 36.
    Garvey TL, Dyer KD, Ellis JA, Bonville CA, Foster B, Prussin C, et al. Inflammatory responses to pneumovirus infection in IFN-alpha beta R gene-deleted mice. J Immunol. 2005;175:4735–44.PubMedGoogle Scholar
  37. 37.
    Lukacs NW, Smit J, Lindell D, Schaller M. Respiratory syncytial virus-induced pulmonary disease and exacerbation of allergic asthma. Contrib Microbiol. 2007;14:68–82.PubMedCrossRefGoogle Scholar
  38. 38.
    Hansbro NG, Horvat JC, Wark PA, Hansbro PM. Understanding the mechanisms of viral induced asthma: new therapeutic directions. Pharmacol Ther. 2008;117:313–53.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2008

Authors and Affiliations

  • Helene F. Rosenberg
    • 1
  • Kimberly D. Dyer
    • 1
  • Joseph B. Domachowske
    • 2
  1. 1.Eosinophil Biology Section, Laboratory of Allergic DiseasesNational Institute of Allergy and Infectious Diseases, National Institutes of HealthBethesdaUSA
  2. 2.Department of PediatricsSUNY Upstate Medical UniversitySyracuseUSA

Personalised recommendations